|
|
Factsheet as on February 28, 2025 |
Factsheet as on February 28, 2025
Structure
Open Ended
Fund Category
Thematic/Sectoral
Fund Manager
Chirag Dagli
Exit Load
Within 1 Month - 0.5%
Fund Size
Rs 2951 crs
Launch Date
November 30, 2018
Investment Objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. However, there can be no assurance that the investment objective of the scheme will be realized.
Market Cap Allocation
Scheme Performance
| 1 Year | 2 Years | 3 Years | 5 Years | |
| Scheme (%) | 9.98 | 31.66 | 19.24 | 24.88 |
| Nifty 500 (%) | -0.69 | 16.99 | 11.58 | 16.55 |
Top 10 Holdings
| Company Name | % of Assets |
| Suven Pharmaceuticals | 10.2 |
| Sun Pharmaceutical Industries | 10.1 |
| Cipla | 8.5 |
| IPCA Laboratories | 7.4 |
| Globus Medical Inc | 6.4 |
| Gland Pharma | 4.8 |
| Illumina Inc | 4.2 |
| Apollo Hospitals Enterprise | 4.0 |
| Laurus Labs | 4.0 |
| Sai Life Sciences | 3.7 |
Year On Year Performance (Scheme V/S Nifty 500)
Ratios:
| Standard Deviation | 15.91 |
| Beta | 0.83 |
| Information Ratio | 0.19 |
| Sharpe Ratio | 0.22 |
Top 10 Sectoral Holdings (%)
SIP Returns
Source: MFI Explorer, Bloomberg.
Please refer to the disclaimer and glossaries
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390